Clinical trials: Old Age
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population
This is a multiple sites phase II trial, randomized, observer-blind, dose ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-based Seasonal VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02236052
- Testing
- Non-adjuvanted low dose of quadrivalent VLP vaccine, Non-adjuvanted medium dose of quadrivalent VLP vaccine, Non-adjuvanted high dose of quadrivalent VLP vaccine
- Where
- 3 sites in Canada
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Medicago
Hereditary Angioedema (HAE)
Donidalorsen Treatment in Children With Hereditary Angioedema
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).
- Trial name
- NCT07298447
- Testing
- Donidalorsen
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 20 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Influenza
Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population
As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy adults, probably as a result of immunosenescence, there is a desire to devise ways to increase the current vaccines efficacy for this…
- Trial name
- NCT00318058
- Testing
- influenza vaccine Fluarix, Adjuvanted Fluarix
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Leukemias
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
- Trial name
- NCT01826214
- Testing
- LDE225
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Insomnia, Adults
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, parallel-group, Bayesian adaptive, dose response study in subjects with chronic insomnia.
- Conditions
- Chronic Insomnia, Adults, Elderly
- Trial name
- NCT01995838
- Testing
- E2006
- Where
- 29 sites in United States
- Volunteers
- 291 people
- Sponsor
- Eisai Inc.
Healthy Subjects
A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects
This study will be a single-center, single dose, randomized, double-blind, placebo-controlled study in healthy Japanese male subjects. The study will consist of 2 parts: Part A (young subjects) and Part B (elderly subjects).
- Trial name
- NCT02289599
- Testing
- E2307
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly.
- Trial name
- NCT01161264
- Testing
- Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Osteoarthritis, Knee
A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee
A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
- Trial name
- NCT04129944
- Testing
- UBX0101
- Where
- 20 sites in United States
- Volunteers
- 183 people
- Sponsor
- Unity Biotechnology, Inc.
COVID-19
Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19
This is a randomized, Open, control phase Ⅳ clinical trial of inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co., Ltd,Beijing institute of Biological Products Co.,Ltd and Wuhan Institute of…
- Trial name
- NCT05165732
- Testing
- Experimental vaccine 1, Experimental vaccine 2, Experimental vaccine 3
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Osteoarthritis, Traumatic Arthritis
Actis Total Hip System 2 Year Follow-up
Two-year (2 year) information regarding the performance of the commercially available Actis™ Total Hip System in order to obtain and evaluate the clinical outcomes on a series of cementless primary total hip arthroplasty (THA)…
- Conditions
- Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congenital Hip Dysplasia
- Trial name
- Actis14014 (NCT02783274)
- Testing
- Actis Total Hip System
- Where
- 9 sites in United States
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- DePuy Orthopaedics
Healthy Participants
Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects
This is a randomized, double-blind, placebo- and active-controlled, 4-period crossover study of lemborexant in healthy adult and elderly subjects to evaluate driving performance
- Trial name
- NCT02583451
- Testing
- Zopiclone 7.5 mg, Lemborexant 2.5 mg, Lemborexant 5 mg
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
The purpose of the Phase I portion of this study is to evaluate the safety of this combination of medications and to determine the appropriate dose of VNP40101M to be used in combination with infusional cytarabine (araC) in…
- Trial name
- NCT00655395
- Testing
- Laromustine (VNP40101M) and Ara-C
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Viron Therapeutics Inc
Denutrition
Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients
Evaluation of the effectiveness and the costs of a quantitative and qualitative nutritional supplementation in elderly patients
- Trial name
- NCT00560729
- Testing
- Renutryl 500, Generique, Generique + Renutryl 500
- Where
- 3 sites in France
- Volunteers
- 63 people
- Sponsor
- Société des Produits Nestlé (SPN)
Influenza
Study of a Pandemic Influenza Vaccine in Elderly Participants
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00376402
- Testing
- H5N1 Pandemic Influenza Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seqirus
Agitation in the Elderly
A Study of BNC210 in Elderly Patients With Agitation
This is a Phase II randomised, double-blind, placebo-controlled study assessing the effects of BNC210 on agitation in hospitalised elderly patients as measured by the Pittsburgh Agitation Scale (PAS).
- Trial name
- NCT03548194
- Testing
- BNC210
- Where
- 5 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Bionomics Limited
Pelvic Floor Disorders
Combination Treatment With BTL-899 and HPM-6000UF Devices
This study will evaluate the clinical efficacy of the BTL-899 and HPM-6000UF devices in combination for non-invasive strengthening of the core muscles and overall improvement in quality of life in elderly patients.
- Trial name
- NCT05537181
- Testing
- BTL-899; HPM-6000UF Treatments
- Where
- 3 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Healthy
Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects
The purpose of the study is to evaluate the amount of compound present in the blood (pharmacokinetics) after single and of multiple doses of GLPG0634 in elderly healthy subjects.
- Trial name
- NCT01665924
- Testing
- GLPG0634 100mg capsule once a day for 10 days
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Influenza
A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine…
- Trial name
- NCT07302256
- Testing
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine, Phosphate buffer solution (PBS)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Type 2 Diabetes
The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.
- Trial name
- STELLA-ELDER (NCT02297620)
- Testing
- Suglat®
- Where
- 8 sites in Japan
- Volunteers
- 8,687 people
- Sponsor
- Astellas Pharma Inc
Acute Myeloid Leukemia
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
The purpose of this study is to evaluate the long-term efficacy and safety profile of tosedostat in elderly patients suffering from refractory or relapsed Acute Myeloid Leukemia.
- Trial name
- NCT01180426
- Testing
- CHR-2797
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Chroma Therapeutics